US · Healthcare · Biotechnology
Analysts rate MiMedx Group Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $7.40.
MIXED MiMedx delivered strong Surgical growth and returned to positive adjusted EBITDA, but Wound Care remains pressured by reimbursement changes and Sanara timing is uncertain. Q3 FY26 No geographic performance breakdown was discussed. Analysts focused on rebate normalization, Wound Care stabilization, Sanara timing, margins, clinical studies, and the path to 20% EBITDA margins. Management emphasized uncertainty around Wound Care and deal timing while defending its cost, evidence-generation, and synergy plans. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| Essex Woodlands Health Ventures | 19.32% |
| BlackRock Inc | 8.33% |
| Nantahala Capital Management, LLC | 6.53% |
| Trigran Investments Inc | 4.92% |
| State Street Corp | 3.82% |
| Vanguard Capital Management, LLC | 3.55% |
| Paradigm Capital Management, Inc. | 2.79% |
| Geode Capital Management, LLC | 2.15% |
| Document | Date |
|---|---|
| Company announcement · Q4 2026 HEADLINE NUMBERS • On October 15, 2026, MiMedx Group, Inc. and Sanara MedTech Inc. each received a “Second Request” for additional information and do | 2026-10-16 |
| Quarterly report · Q2 2026 MIMEDX GROUP, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales Q2 2026: $64.4 million (down 34.7% vs. Q2 2025: $98.6 million) • Net sales H1 | 2026-07-29 |
| Results announced · Q3 2026 MIMEDX GROUP, INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $64 million (down 35% vs. $99 million in Q2 2025) • Six-Month 20 | 2026-07-29 |
| Material agreement · Q3 2026 MIMEDX GROUP, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Consideration per Sanara Share: $33.00 cash + 0.4735 MiMedx shares (stock valued at | 2026-07-29 |
| Charter / bylaws change · Q2 2026 MIMEDX GROUP, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting Date: June 10, 2026 • Shareholder Participation: 125,360,965 shares represen | 2026-06-16 |
| Quarterly report · Q1 2026 MIMEDX GROUP, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Net sales Q1 2026: $58.991 million (down 33.2% from $88.205 million in Q1 2025) • Net loss Q | 2026-04-29 |
| Proxy statement · Q4 2025 MIMEDX GROUP, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect seven directors: Joseph H. Capper, James L. Bi | 2026-04-29 |
| Results announced · Q2 2026 MIMEDX INVESTOR SUMMARY – APRIL 2026 HEADLINE NUMBERS • LTM Net Sales (Q1 2026): $388 million • LTM Adjusted EBITDA: $148 million (38% margin) • Net | 2026-04-29 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MiMedx Group Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.